Podcasts about biotech companies

"The moment of discovery, that sense of awe and wonderment, is something I wish every scientist could experience."In this captivating episode, Professor Andrew Wilks takes us on a journey from the council estates of Liverpool to the forefront of molecular cancer biology. A scientist-turned-entrepreneur, Andrew's career spans the discovery of JAK proteins, founding 12 biotech companies, and achieving the rare trifecta: discovering a protein, developing a therapeutic molecule, and creating a medicine that changes lives.Andrew's story is one of curiosity, resilience, and unwavering determination to make a difference in cancer research and beyond.In this episode, Andrew shares:The exhilaration of finding something no one else ever has.Managing the emotional highs and lows of scientific breakthroughs.Transitioning from academia to entrepreneurship and the lessons learned along the way.Nurturing young scientists to experience their own "numinous" moments.Host: Jenelle McMaster Deputy CEO Oceania and Markets Leader at EY.Guest: Prof Andrew Wilks Molecular biologist and cancer cell biologistListen now: Apple Podcasts or Spotify or wherever you get your favourite podcasts.

This week I chatted with Renee Williams, Founder and Managing Partner at Williams Biotech Consulting. Renee is a seasoned fractional Chief Business Officer (CBO) for small and growing biotechnology companies. Renee shares her career path, insights into helping biotech startups secure funding and navigate partnerships, and the importance of adaptable strategies in a constantly evolving market. From term sheet negotiation to pitch deck reframes, Renee offers valuable advice and lessons for small companies. We also dissect her engagement tactics during major conferences like JP Morgan and the essential factors for biotech success.Get Renee's recommended book! The 3-Minute Rule: Say Less to Get More from Any Pitch or PresentationLink In with Renee!Connect with us!Link In with CarinaSubscribe here:AppleSpotifyGoogle PodcastRSS feedLearn more about Recruitomics ConsultingCheck out our reading listDownload our free startup resources guide to grow your biotech efficientlyIf you're on the job market, visit the Collaboratory Career Hub 00:00 Introduction and Childhood Dreams01:19 The Power of Dressing the Part01:49 Career Path and Consulting Firm03:20 Role of a Fractional CBO04:03 Navigating Startup Challenges06:07 Crafting Effective Pitch Decks08:32 Big Pharma vs. Biotech Mentality16:01 The Importance of a Strong Team in Biotech16:20 Approaching Pharma and Corporate Venture Capital17:20 Strategies for Biotech Companies to Gain Traction18:24 Types of Biotech CEOs and Their Approaches21:02 Navigating Conferences and Networking27:09 Future Goals and Aspirations28:59 Book Recommendations and Closing Thoughts

Are you navigating the complexities of forming and maintaining corporate partnerships in biotech? In this episode, we sit down for a conversation with Tari Suprapto, PhD, the Director of Search and Evaluation at Novo Nordisk, who offers valuable tips on managing relationships between academic and corporate partners (that are also useful for smaller companies looking to interact with larger ones). Host Kaneisha Akinpelumi dives into the importance of personal connections, shared goals, and effective communication in successful partnerships. Dr. Suprapto also shares her experiences dealing with imposter syndrome in high-stakes environments. In this episode, you'll discover: Strategies for fostering strong academic-corporate partnerships in the biotech sector. The critical role of communication and shared goals in sustaining these relationships. Tari Suprapto's insights on overcoming imposter syndrome while navigating the biotech industry. Tune in to gain actionable advice on building and maintaining successful partnerships in biotech. Links: Connect with Tari Suprapto, PhD, and learn about Novo Nordisk. Check out Dr. Suprapto's BIO on the BAYOU panel: Conversation with Corporate Colleagues. Connect with Kaneisha Akinpelumi and learn about Xavier University of Louisiana's Office of Research and Sponsored Programs. Check out BIO on the BAYOU and make plans to attend October 29 & 30, 2024. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

How do small biotech companies make strategic decisions with limited resources? This episode dives deep into the art of prioritization and outsourcing to achieve success.Join us as we speak with Mark Melville, Vice President of CMC, Biologics at Cullinan Therapeutics, a seasoned biotech scientist with years of experience in both large and small biotech companies. Mark shares his invaluable insights on navigating the complexities of bioprocess development and outsourcing.In this episode, we explore:Discover the secrets to prioritizing projects for maximum impactLeverage outsourcing for flexibility and expertiseLearn to build strong relationships with external vendors to ensure top-notch quality and regulatory compliance.Connect with Mark Melville:LinkedIn: https://www.linkedin.com/in/mark-melville-a9a43b2Next Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Are you navigating the complex world of bioprocess CMC development and manufacturing in a small biotech company?Our latest episode is a must-listen! Join us as we sit down with Mark Melville, Vice President of CMC, Biologics at Cullinan Therapeutics, who shares invaluable insights on overcoming the unique challenges faced by small biotech firms.In this episode, we explore:The critical communication strategies needed for successful outsourcing to CDMOs.How small biotechs can leverage their agility to make fast, impactful decisions.The surprising benefits of wearing multiple hats and fostering cross-functional expertise.Tune in to discover how mastering these areas can help your small biotech thrive and stay ahead in a competitive market.Don't miss this opportunity to gain practical advice and turn your challenges into advantages!Connect with Mark Melville:LinkedIn: https://www.linkedin.com/in/mark-melville-a9a43b2Next Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

So many amazing Canna-people, so little time. CannMed 24 was sublime! Here are the another batch of clips we got!Ben Cameransi – Mingowood Pharmacal, LLC - Dr. Benjamin Cameransi, MD, DABA is a Board-Certified Anesthesiologist, with a extensive background in pain management. He has started four Biotech Companies. He was involved in the development of Ryanodex™, a treatment for Malignant Hyperthermia. But wait, there's more… Acidic cannabinoids aren't very stable when they are extracted and purified. Dr. Camersani's team at Mingowood Pharmacal has a way to fix that.Taz Turner -CordovaCann Corp - Taz has the top three attributes we look for in a guest. He knows where Manitoba is located. He's a finance guy who spoke intelligently during his Capital Markets Panel. He is fun to chat to at a breakfast information session. Taz tells us how it is surprisingly difficult to get investment into the cannabis space in 2024. But, numbers and valuation guys like him (who also speak cannabis) are slowly convincing others that opportunities abound.Melissa Moore - Professor, Cannabis Horticulture & Biology, SUNY Niagara Community College. Melissa Moore developed some of her horticultural chops in Northern California, but now passes on her knowledge in Buffalo, NY. She was very helpful getting pics of Trevor during his Capital Markets Panel and then she sparked some intense Aspergillus discussions. Professor Moore tells us why cleanliness is next to godliness in your grow room and, hear why Kirk is frothing at the mouth to pick her brain about how to grow plants better.Ben Cameransi - LinkedInMingowood Pharmacal, LLC - WebsiteTaz Turner -LinkedInCordovaCann Corp. - websiteMelissa Moore - LinkedInSUNY Niagara Horticultural Cannabis Classes - websiteMusic by:Stills-Young Band - Midnight on the Bay -YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

In this week's episode of The Data Minute, Peter Walker (Head of Insights at Carta) sits down with Darren Cooke (Executive Director, Berkeley Life Sciences Entrepreneurship Center) for an enlightening discussion about some emerging trends with biotech companies: Namely, while pharma and biotech currently rank as the 5th most-funded type of pre-seed startups, they simultaneously enjoy favorable valuations to other SaaS-type businesses.This leads Peter and Darren into a conversation about biotech, the challenges and differences for biotech founders when raising seed capital, and of course, Darren's history and experience leading Berkeley's accelerator program, SkyDeck — one of the most celebrated accelerators in the startup world.Subscribe to Carta's weekly Data Minute newsletter:https://carta.com/subscribe/data-newsletter-sign-up/Explore interactive startup and VC data, with Carta's Data Desk:https://carta.com/data-desk/Chapters:00:00 Intro00:44 Darren Cooke, Berkeley Life Sciences Entrepreneurship Center02:05 Berkeley SkyDeck04:39 The pre-seed experience for biotech companies08:22 Regulation, reimbursement, and outside funding10:29 Round sizes in the biotech industry12:27 Investor interest in biotech16:42 The five stakeholders biotech companies need to know21:15 Pre-seed fundraising and priced rounds23:27 Demo day25:52 Words of adviceThis presentation contains general information only and eShares, Inc. dba Carta, Inc. (“Carta”) is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services, and is for informational purposes only.  This presentation is not a substitute for such professional advice or services nor should it be used as a basis for any decision or action that may affect your business or interests. © 2024 eShares, Inc., dba Carta, Inc. All rights reserved.

Stop Starvation Marketing – 23 Power Growth Moves for Health Tech, IT and Biotech Companies is the new book by Christine Slocumb, founder of Clarity Quest, an innovative marketing and PR agency that is part of Supreme Group. On this episode, Carol Flagg and Chris, who is now the Chief Growth Officer for Supreme, discuss some of the chapters and anecdotes from the book. Learn more about her book at https://www.clarityqst.com/resources Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Biotech companies, such as Generate Biomedicines and Montai, are utilizing artificial intelligence (AI) to enhance the drug development process. Generatehas trained their AI to design new proteins that do not exist in nature, expanding the scope of disease-treating proteins. They have already generated approximately 5 million of these proteins and are focusing on autoimmune conditions, cancer, and infectious diseases. The company's AI-assisted drugs for asthma and a COVID-19 monoclonal antibody treatment are entering the first phase of clinical trials. Similarly, Montai uses AI to analyze natural molecules and identify substances that could target specific pathways in the body. Over 125,000 potential substances have been identified for developing treatments for chronic illnesses. However, the success of these AI-assisted treatments will depend on clinical trials. While AI in drug development offers promise, it still requires significant human work and faces challenges such as data gaps and limitations. --- Send in a voice message: https://podcasters.spotify.com/pod/show/tonyphoang/message

Join us as we discuss with Hartaj Singh the essential elements of messaging in the public biotech arena, and his advice to management teams of early-stage companies.

Pete Blaber commanded at every level of one of the most elite counter-terrorist organizations in the world, The US Army's First Special Forces Operational Detachment Delta. His time with The Unit included most of recent history's significant military and political events (Panama, Colombia, Somalia, Bosnia, Afghanistan, and Iraq). In 2006 Pete retired from the military and transitioned from leading elite combat teams around the globe, to leading elite corporate teams for one of the world's largest and most innovative Biotech Companies.Pete's first book “The Mission, The Men, And Me, Lessons From a Former Delta Force Commander,” is one of the most widely read books among tactical units and is required reading at many tactical leadership programs. His second book, “The Common Sense Way, A New Way to Think About Leading and Organizing" which builds on the legacy of the first book providing specific and concrete guidance on how to implement common sense into your leadership style. His third, and most recent book “Common Sense Leadership Matters: Toxic Leadership Destroys” is a case study of the death of Pat Tillman and how Toxic Leadership led to Tillman's death at the hands of friendly fire.Pete has an MBA and an MS in National Security and Strategic Affairs.I am excited to speak to Pete not only because he lead one of the most elite combat units, but because he is a very deep thinker on the topic of leadership and has a unique ability to articulate his lessons learned and his research in a very practical and down to earth fashion. I hope you enjoy my chat with Pete Blaber.Contact Infohttps://www.peteblaber.com/Books RecommendedThe Mission, The Men, and Me: Lessons from a Former Delta Force Commander by Pete Blaber - ISBN-13: 978-0425223727The Common Sense Way: A New Way to Think About Leading and Organizing by Pete Blaber - ISBN-13: ‎978-0578995878Common Sense Leadership Matters: Toxic Leadership Destroys by Pete Blaber - ISBN-13:‎ 979-8218224837

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Priya Baraniak, Chief Business Officer at OrganaBio. Join us as Priya shares her career journey from aspiring astronaut to leading in the field of regenerative medicine and her passion for making therapies more accessible and empowering the next generation of girls. She also gives valuable insights on being a CBO in the biotech industry, and the challenges and growth of early-stage start-ups.

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Dr. Denis Drygin, Co-Founder at Pimera Therapeutics, Inc. Come with us as we uncover Denis' passion for RNA-targeting therapeutics, the serendipitous nature of drug discovery, and the importance of global collaboration for drugs development and clinical trials. We also discuss the challenges and fulfillment in drug development for a founder in the biotech industry.

Stop Starvation Marketing: 23 Power Growth Moves For Health Tech, IT, Biotech Companies by Christine Slocumb ABOUT THE BOOK: Get ready to embark on a journey through 23 power moves that will help you grow a successful healthcare, biotech, or IT company.  With practical tips and real-world success stories, Stop Starvation Marketing is a must-read for tech leaders looking to take their marketing to the next level.  Every chapter is packed with tactics, tips, and punchy anecdotes that immediately demonstrate each point. Action strategies are clearly outlined and provide a blueprint for success. If you are serious about marketing results – and enjoy a spot of humor along the way – this book is for you. ABOUT THE AUTHOR: Christine has 30 years of marketing, business development, and product management experience in a wide variety of companies, from start-ups to Fortune 50 firms.  Since founding her marketing firm Clarity Quest in 2001, Christine has worked with technology, life sciences, and healthcare firms on marketing strategy, business planning, and marketing implementation.  Christine earned undergraduate and graduate degrees in electrical engineering, and an MBA – and holds eight U.S. patents. And, interesting fact - Christine and the host of The Marketing Book Podcast are both married to physicians! Click here for this episode's website page with the links mentioned during the interview... https://www.salesartillery.com/marketing-book-podcast/stop-starvation-marketing-christine-slocumb 

This time on Building Biotechs: A Podcast by Recruitomics Consulting, Balaji Vasudevan, Agrobioscience Chief Scientist at UM6P Ventures, joins us to discuss the current challenges and opportunities in the AgTech and Agri-FoodTech industry, the importance of sustainable agriculture, and the potential impact of new technologies on global food production.

This time on Building Biotechs: A Podcast by Recruitomics Consulting, Lysa Miller, Founder and CEO of Ladybugz Interactive Agency, joins us to discuss what it's like working with a stealth to startup companies, especially when it comes to their marketing, and why pitch decks are so important for biotech startups!

This time on Building Biotechs: A Podcast by Recruitomics Consulting, Robert Buckley, Chief People Officer at Enveda Biosciences, joins us to talk all about why data isn't the only answer in biotechs, how to leverage data in the hiring process, how to take feedback as a gift, and training non-science people in biotechs.

This time on Building Biotechs: A Podcast by Recruitomics Consulting, Lynn Walder, Founder & Principal of Executive Management Partners and Director of Partnerships Programming at LabCentral, joins us to discuss why you should never give up on your startup; whether it's better to work in a big business or a small startup; how to overcome burnout; and whether there is any such thing as work-life balance.

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Eva Quinn, Senior Human Resources Business Partner at Higher EQ. Join us as we discuss some of the biggest challenges in biotech HR and what makes it such a unique profession in the industry; the importance of mental health in the workplace; and how HR plays such a vital role in biotech.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. In our first news, Bayer shares fell by 20% after a study monitors halted a planned 18,000-person trial of its experimental blood thinner drug due to "inferior efficacy" compared to Eliquis. Bristol Myers is also facing a delay from the FDA on a decision regarding its cancer cell therapy. Astrazeneca has created a digital health unit called Evinova to tap into the growing market for digital health solutions. And fewer biotech companies are going public, but Carmot Therapeutics has filed plans to go public in hopes of capitalizing on investor interest in obesity medicines. Janet Woodcock, a top FDA official, will retire early next year after 37 years with the agency.Moving on to our second news, the Federal Trade Commission has filed a lawsuit to block John Muir Health's acquisition of Tenet Hospital, claiming it would reduce competition and increase prices. Mass General Brigham is being sued after potential exposure to HIV and hepatitis at Salem Hospital. Nurses and medical professionals are planning a five-day strike at HCA facilities in southern California. On the other hand, Novant Health plans to buy three Tenet hospitals in South Carolina for $2.4 billion. Telehealth is also highlighted as a growing trend for routine and mental healthcare.Next up, Bayer's investigational factor XIA inhibitor was found to be inferior to Pfizer and BMS' blood thinner Eliquis in a Phase III study. The UK's National Health Service has reached a new deal with pharmaceutical companies that doubles the annual allowed growth in sales of branded medicines. Carmot Therapeutics is planning to make its debut on the NASDAQ stock exchange. Servier is considering filing for FDA approval for its glioma candidate vorasidenib.Lastly, Biohaven aims to develop a novel drug called taldefgrobep alfa that can treat spinal muscular atrophy (SMA) as well as trim fat and build lean muscle mass in obese individuals. Clinical trial diversity has decreased, prompting companies to refine their diversity, equity, and inclusion strategies. The development of new drugs that can address multiple health issues simultaneously shows promise for improving patient outcomes and expanding treatment options.These developments highlight the challenges faced by pharmaceutical companies in developing new drugs and the importance of partnerships between healthcare systems and industry players to advance research and improve patient outcomes.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates.

This time on Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Mike LaRhette, Chief Business Officer at LabCentral. We discuss juggling responsibilities in biotech; how biotechs are saving the human race; the most important components of an entrepreneurial ecosystem; and some of the biggest obstacles when working with partners.

This time on Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by two brilliant (and funny) people: Joe Daccache, Project Leader at DeciBio, and Carl Schoellhammer, Principal at DeciBio and Founder of Suono Bio. Join us as we explore the sheer grit and motivation it takes to build a startup and what it takes to discover potential client's in that early phase of start-up.

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by David Cao, Founder of Target2Drug BioAdvisory. Join us as we delve into the differences between biotech advisories and consultancies, and why working with startups is such a joyful experience!

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Paul Miller, a leading science officer in the field of biopharmaceuticals and Founder of Lighthouse Biopharma Consulting. Join us as we delve into the world of biotech, discussing Paul's impressive career journey, his new consulting venture, insights into leadership and mentoring in the biotech world, and the role of AI in the biotech sphere.

Dr. Alex Colville, Ph.D. is Co-Founder and General Partner of age1 ( https://age1.com/ ), a venture capital firm focused on catalyzing the next generation of founder-led, longevity biotech companies, with a strategy of building a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related diseases. With a recent initial closing of US$35 million, age1 will be focusing on founders and companies at the earliest stages of first-money in, pre-seed and seed funding, and is resourced to continue to support companies through later rounds. Dr. Colville previously established the biotech arm of Starbloom Capital and served as founding Chief of Staff of Amaranth Foundation, where he led: the foundation's support of skilled researchers and ambitious moonshot projects in the longevity field, and helped to advance their lobbying efforts; the TIME Initiative (a group with mission to activate undergraduate students' interest in aging biology); the Marine Biology Laboratory Biology of Aging Summer Course, among other programs. Dr. Colville completed his Ph.D. in Genetics at Stanford University studying the biology of aging in Dr. Thomas Rando's lab while consulting for several family offices, the R&D team of Rubedo Life Sciences, and the business development team of Maze Therapeutics. Prior to his Ph.D., while at Northeastern University completing his Bachelor of Science (B.S.) in Chemical Engineering with a Minor in Biochemical Engineering, he advised pharma companies as a management consultant at Putnam Associates, a boutique life sciences consulting firm. Support the show

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Trice Alford, Chief Marketing Officer at Ronawk, to unveil the exciting world of marketing in the biotech sector. He shares the challenges of marketing for biotech startups, the influence of AI in marketing, and the importance of knowing your customers.

OIS Podcast host Carey Powers caught up with four ophthalmology execs and one principal investigator to talk about some of the most exciting developments in retina R&D.Her guests include:Houman David Hemmati, MD, PhD, Cofounder and Chief Medical Officer of Optigo Biotherapeutics   Michael Tsipursky, MD, CEO and Cofounder of Revive BiotechMichael Singer, MD, Clinical Professor of Ophthalmology at University of Texas Health Science Center, Director of Clinical Research at Medical Center Ophthalmology Associates, and Principal Investigator for Unity Biotechnology's BEHOLD trialSamarendra Mohanty, PhD, President and Cofounder; and Sulagna Bhattacharya, CEO and Cofounder of Nanoscope TherapeuticsOptigo is developing binders intended to extend the duration of top-performing intravitreal drugs without compromising efficacy. The company has already had promising results in clinical trials with aflibercept. What's next?Revive Biotech focuses on central retinal artery occlusion. Its products work by injecting oxygen-loaded nanobubbles into the eye intravitreally. Preclinical studies have advanced through proof of concept. Nanobubbles?Dr. Singer is a principal investigator in Unity Biotechnology's clinical trial for UBX-1325, a therapeutic in development to treat diabetic macular edema and wet AMD. If approved, the product could work as an adjunct to anti-VEGF therapies.Nanoscope Therapeutics is developing gene therapies that focus on ambient light-sensitive molecules to treat inherited and acquired retinal diseases. Its lead product, MCO-010, is moving through Phase II trials. Why ambient light?Tune in to hear today's experts discuss:How Optigo plans to extend the duration of afliberceptThe impact of extending duration activity on patients, physicians, and payersWhat Optigo plans to accomplish over the next 12 monthsWhat's behind Revive Biotech's proprietary technology and what makes it unique.The milestones it has completed so far with relation to clinical trials, intellectual property, and fundingThe new class of therapeutics being developed by Unity BiotechnologyThe data released so far on the UBX-1325 BEHOLD trialIf approved, the impact of UBX-1325—an agent that may potentially extend the life of anti-VEGF therapies—on clinical practiceThe potential impact of Nanoscope Therapeutics's MCO-010 on patient communitiesThe feedback reported from clinical trial participantsThe critical milestones Nanoscope Therapeutics intends to achieve over the next year[Listen Now]

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Kevin E. Johnson, Human Capital Professional. Together, we delve into his views of the biotech industry from a HR and Human Capital perspective, highlighting the need for effective and open communication across all areas of the industry.

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Tiffany Summerville, Vice President of Human Resources at Sherlock Biosciences! Together, we delve into the importance of diversity and inclusion in the industry, leadership development, and effective communication strategies.

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Leslie Martin, Vice President of Talent Acquisition at Flagship Pioneering! Today, we get into why someone who had never worked in biotech decided to move to the industry; why you should let your biotech founders focus on the science; and the importance of creating an inclusive, diverse working culture.

In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Adam Thomas, Chief People Officer at Synlogic! Together, we delve into the major differences between bigger biotechs like Pfizer and smaller ones like Synlogic and how to identify and nurture the future leaders within your company.

In the eighth episode of this season, we chatted with Alex Sapir about his various experiences leading life sciences companies through commercial launches and key funding milestones. We spoke about his career beginnings at GSK, ZS Associates, and United Therapeutics. Additionally, we covered his CEO tenures at Dova Pharmaceuticals and ReViral Ltd - both of which were acquired.

Phil Carroll and Kevin Hornsby talk to Che and Geoff regarding the recent City-Mix Commercial Progress Update. 3DBT have engaged with over 60 Cellular Agriculture companies of which 26 have progressed to new business opportunities, representing a 43% conversion rate. From these 26 business opportunities, 22 product evaluations are already underway with a view to incorporating City-Mix into cultured media formulations. A further two companies have also completed successful evaluations and are expected to begin purchasing the product in April 2023. As well as Cellular Agriculture companies, which are involved in the production of cultured meat, leather and media, 3DBT has identified two other key target markets. These are Biotech Companies, such as those working in gene therapy, stem cells and regenerative medicine; and Life Sciences companies and academia, which research the above disciplines. Disclaimer & Declaration of Interest The information, investment views, and recommendations in this podcast are provided for general information purposes only. Nothing in this podcast should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.

Get ready to light up the conversation with finance expert Seth Yakatan as he spills the tea on the cannabis and biotech industries. Despite cannabis interest being at an all time high, the industry needs to weed out a ton of regulatory and technical hurdles. Join in as Seth shares how biotech is shaking things up in the cannabis world, from production to consumer goods. They'll also explore clinical trials and synthetic compounds, and highlight innovative companies and products. Get in the weeds on the future of bioengineering cannabis, and toke up some valuable insights. Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space.  Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 00:00:00 The Biology of Climate Change 00:01:06 Mild NYC Winter: Climate Change? 00:04:24 California and NY Legalize Cannabis 00:05:52 Life Sciences: A Family Influence 00:08:41 The Endocannabinoid System and Homeostasis 00:11:13 Epidiolex: Treating Epilepsy with Cannabis 00:13:59 Constraints in Cannabis Pharmaceutical Development 00:18:50 Tikkun Olam's Vehicle Strain: Phase Zero Testing 00:23:31 Constraints of the Cannabis Market 00:28:40 Synthetic Cannabis Production Attempts Fail 00:32:01 Exploring Compounds for Alternative Effects 00:36:44 Federal Change on Alcohol and Cannabis Regulation 00:41:19 Biotechnology and Cannabis: Novel Form Factors 00:43:07 Limited Capital for Biotech Companies 00:45:22 Biotech and Cannabis: Similarities and Opportunities 00:47:00 High-Quality Greenhouse Flower Production Profits 00:50:41 Investment in Canadian Cannabis by Pharmaceuticals and Tobacco 00:52:46 Consolidation in the Cannabis Beverage Industry 00:57:27 Factors in Industrial Cannabis Growth 00:59:29 Plant Engineering for Flavor Enhancement 01:02:26 Synthetic Biology and Cannabis Farming 01:07:17 Exploring Biotech Possibilities with Seth Episode Links: Seth on LinkedIn Katan Associates GW Pharmaceuticals 1906 CANN Uncle Arnie's Glass House Group Forefront Ventures Pacific Stone Call or Text the Grow Everything Hotline:  +1 804-505-5553 Have a question or comment? Message us here: Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message

Welcome to the latest episode of Grow Everything, where we take a deep dive into the fascinating world of soil health and the incredible power of engineering organisms. Our hosts Karl and Erum are joined by the amazing Nicole Richards, a 28-year veteran in the chemical space and CEO of Allonnia. Nicole shares her valuable insights on how biology can be harnessed to solve some of our biggest challenges and transform waste into valuable resources. We discuss the exciting new lab in Brooklyn, which has been generously funded by city and state money, as well as sustainable birthday boxes and event swag made from bio-based materials. Lastly, we learn about Allonnia's groundbreaking work in extracting rare earths from mine waste sites and using biology to treat contaminants. Tune in to hear from a true expert and discover how you can get involved in this exciting field!  Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space.  Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered:  00:00:00 - "Waste Is A Failure of Imagination": Exploring The Need For Innovative Solutions  00:03:23 - The Role of Biotech Companies in Waste Management and Habits Change  00:05:49 - Brooklyn's New Lab: Investing in Garbage and Biotech for a Cleaner Future  00:11:37 - Federal Regulations: The Need for Cleanup of Unhealthy Practices  00:15:58 - Soil Contamination Analysis: Unpacking The Complexities  00:23:07 - From Chemical Engineering To Biotech: Leveraging The Benefits Of High Throughput Automation  00:25:51 - Chemical Companies Investing In Biotech To Solve Environmental Problems  00:30:44 - Waste As A Resource: A New Consciousness And Innovative Solutions  00:37:32 - Exploring The Impact Of Landfills And Waste On Society's Health And Wellbeing  00:41:32 - Nicole's Story: Appreciating Allonnia's Sustainable Approach To Waste Management  00:43:53 - Regenerative farming: Probiotic for soil health  Episode Links:  Nicole Richards on LinkedIn  Allonnia's Website  Wall-E movie Donate to Turkey-Syria Earthquake Relief: Direct Relief Disaster Philanthropy Call or Text the Grow Everything Hotline:  +1 804-505-5553 Have a question or comment? Message us here: Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message

In the latest episode of Grow Everything, hosts Karl and Erum welcome guest Shelby Newsad, a venture capitalist at Compound VC and a graduate of the University of Cambridge where she studied Bioscience Enterprise and Philosophy. Karl and Erum discuss the thriving biotech industry in New York City and the impact of Indie Bio on the state. Shelby sheds light on the exciting new companies being formed, tackling diverse challenges in the biotech field such as hormone monitoring for women and veterinary drugs utilizing cannabinoids. Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space.  Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 00:00:00 Uncovering the Vital Role of Petrochemicals in Shaping Our Planet and Health  00:04:07 A Deep Dive into Biotechnology with a NY Insider  00:09:01 Moving Beyond Automation: A Broader View of the Biotech Industry  00:10:29 Investing in Protein Degradation: A Pathway to Change and Better Health  00:16:45 Balancing Opportunities and Risks in Consumer Biotechnology  00:22:13 An Insider's Perspective on the NYC Biotech Scene after Six Months  00:26:28 The Power of Early-stage Investment in Biotech Companies  00:27:54 Building a Complementary Business Through Strategic Investments  00:33:26 Fermentation's Role in the Future of Consumer Biology  00:37:55 Celebrating Brilliance: An Interview with Cambridge Grad Shelby on Biotechnology Episode Links: Shelby Newsad's LinkedIn Shelby's Substack Call or Text the Grow Everything Hotline:  +1 804-505-5553 Have a question or comment? Message us here: Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media Topics: synthetic biology, entrepreneurship, policy, community, science education, biotech, life sciences, community biolabs, bioliteracy --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message

Episode Description:  In this episode of Grow Everything, Alexis discusses the challenges and benefits of scaling a biotech product in the leather industry. He shares how his company, Polybion, has strong partnerships with leather manufacturers that enable them to rapidly prototype new products. Alexis also talks about their facility in Ensenada, which is powered by solar energy and recycles water for use in growing batches of their biotech product. He explains that this product is not meant to replace traditional animal leather, but rather offers similar performance for up to 70% of the market. Additionally, Alexis discusses the possibility of hiring employees from abroad and working remotely, as well as the potential for using synthetic biology to create bio materials and materials for use in space or other planets.  Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space.  Life is a powerful force and it can be engineered. What are we creating?  Learn more at www.messaginglab.com/groweverything  Topics Covered:  00:00:00 Focus On Scale And Yield: The Brothers' Visionary Approach to Biotech Production  00:04:14 Growing Up Entrepreneurs: A Family's Experience in the Biotech Industry  00:07:50 Investor Pushes For Leather Application With Microbial Technology  00:13:08 Exploring The 200-year-old Leather Tradition In Leon, Mexico and Its Potential for Biotech Advancements  00:18:47 Exploring Remote Hiring And Working In San Miguel for Biotech Companies  00:25:25 Creating A New Textile: Comparing Performance Of Animal Leather And Biotech Leather Alternatives  00:27:38 Exploring Synthetic Biology For Materials And BioMaterials Production 00:33:13 Leather Industry Worries Over Potential Shift towards Biotech Leather  00:35:14 Leather Industry's Resistance To Change and Adoption of Biotech Materials  00:40:14 The Beauty Of Local Organic Waste: Crafting Leather From Microbes Using Sustainable Practices  00:42:35 Material Used For Liquid Leggings and Its Potential for Biotech Production  Episode Links:  Alexis Gómez-Ortigoza Linkedin  Polybion Website  Episode Transcript Call or Text the Grow Everything Hotline:  +1 804-505-5553 Have a question or comment? Message us here: Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Topics: bioeconomy, biomanufacturing, Biotechnology, synthetic biology, entrepreneurship, biomaterials, leather, leather industry, sustainability, circular economy, waste management, climate technology, startup, scalability, capitalism 2.0, microcosmos --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message

In this Silicon Valley Tech & AI episode presented by GSD Venture Studios Gary Fowler interviews Mel Larossa. Mel Larossa CEO, Innovation Center | Schneider Children's Medical Center of Israel Mel Larrosa specializes in developing industry partnerships in the Life Sciences, Biotech and Pharma sectors. Originally from Brazil, Mel brings 18+ years of experience in ideation, tech evaluation, market analysis, IP strategy, regulatory affairs, business modeling, and contract negotiation, leading to hundreds of commercial deals and to the establishment of 20+ well-funded startups. All done in multicultural environments - Israel, Europe, US, LATAM, India, China. She served at the Board of Directors in several Biotech Companies. Mel holds an MBA from Open University and an MSc in Molecular Biology from the University of Brasilia. She earned her BSc in Biology from the University of São Paulo and is currently pursuing an additional MSc in Nutrigenetics & Nutrigenomics.

Andrew Casey is the President and CEO of BIOTECanada. Prior to joining BIOTECanada, he served as the Vice President, Public Affairs and International Trade and Vice President, Government Relations and Communications for the Forestry Products Association of Canada. He was also the Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association.-----Read or watch his full interview and key takeaways: https://bit.ly/3dHZdDY-----Follow us for more interviews on Canada's future economy:YouTubeTwitterLinkedIn

With fewer people covering more roles with less specialization and novel therapeutics with unique testing requirements, the needs of small biotech companies in clinical trials are different from larger sponsors. In this episode, Alex Watt, Global Head for Biotech Integrated Laboratory Solutions and Mona Henderson, Director of Laboratory Network Solutions (both at Q2 Solutions) discuss how our dedicated biotech teams focus specifically on the unique needs of those customers. Alex and Mona cover: Operational strategy, from supply chain to data management The role of LNS in contracting and managing specialty, third-party labs Collaboration with our parent company, IQVIA and Adapting to evolving customer strategies  You can learn more at https://q2labsolutions.com/biotech.  

In this episode, Alex Watt, Global Head for Biotech Integrated Laboratory Solutions and Alan Wookey, Global Head of Companion Diagnostics discuss how to manage both scientific and operational risk in clinical trials for biotech companies. Looking at risk as uncertainty reveals not only threats to project timelines but also opportunities to take a new approach.  Alex and Alan talk about: How different risks are evaluated and prioritized and the processes put in place to mitigate and/or respond to those risks if they occur.  What sponsors can do to reduce the risks for their study How Q2 Solutions' in-house scientific and regulatory expertise ensure that your data are compliant to global regulations You can learn more at https://q2labsolutions.com/biotech.

01-20-2022 Dr. Mark Swaim Learn more about the interview and get additional links here: https://www.usadailychronicles.com/these-small-cap-biotech-companies-may-be-the-most-undervalued-on-the-market-today/ Subscribe to the best of our content here: https://priceofbusiness.substack.com/ Subscribe to our YouTube channel here: https://www.youtube.com/channel/UCywgbHv7dpiBG2Qswr_ceEQ

Part 2 of the Year in Review Recording. 1 hour 15 minutes of exciting conversations with speakers from previous podcast episodes and business partners of the hosts. What was hot in 2021, and what do our speakers expect for 2022?In this episode, we talk aboutHealth Literacy and the Healthcare SystemVenture Capital in 2021Digitalization in Drug DevelopmentThe Golden Age of BiotechHome Office – How Work-Life will Look like in the Post Pandemic WorldI hope you enjoy the conversation the same way I did.Who are the Experts in this episode:Bettina ReslSascha BergerTilmann BuerckstuemmerThomas MoserKimberly CornfieldVideo to the Episode: https://youtu.be/HL-z1c_1XaUTimestamps:(02:00) Bettina Resl - Christmas Greetings(03:11) Review of 2021  - Challenges for the Healthcare System in 2021 Beyond Covid 19(06:32) Healthy Habits are the First Step to Longevity(07:32) How Do Pharma Reach Patients?(09:12) The Importance of Health Literacy – Concept and Strategies to Improve Health Literacy for the People(16:56) What Happens to Home Office in a Post-Pandemic World(20:00) Sascha Berger – Recap of 2021(21:45) Significant closings in the Life Science VC world during the pandemic(22:57) Lasting Effects of the Capital Flow Towards Life Science(25:20) Will the Development Speed in the Pharma Industry in 2020/21 be Lasting?(29:17) The Digital Revolution – Does it Affect the Dealflow of Life Science VCs?(31:55) Outlook for 2022(32:25) Conference Plans for 2022(33:29) Thomas Moser and Tilmann Buerckstuemmer – Aelian Biotechnology(35:33) Aelian Biotechnology – This was 2021(36:00) Bit.BioDiscovery – Finding New Cell Types – The Holy Grail of Biology(37:14) Outsourcing Trend for Pharma and Biotech Companies(38:00) Trend to Digitalisation(39:38) Data – Is it More Signal or More Noise?(41:39) CRISPR - Trends(42:40) The Golden Age of Biotech(44:18) What is the Big Goal for The Holy Grail of Biology?(46:34) Golden Age of Biotech or Bubble Territory?(47:39) Increasing Health and Financial Literacy for the Common Good of Society(48:18) Data Security in Gene Editing(49:42) Paradigm Shift in Data Storage(54:38) Outlook for 2022 – Aelian Biotech(57:00) Astrid Wollard and Matthias Tarasiewicz – Recap of 2021(58:51) Talent Shortage(01:01:15) Web 2.0 vs. Web 3.0(01:01:55) Use-Cases in Web 3.0 Beyond Token(01:02:00) Kimberly Cornfield - Intro(01:02:30) Research Activities at the UCL in Web 3.0 and Beyond(01:04:00) European Research & Innovation at the UCL(01:05:00) Effects of the Brexit on European Collaboration with British Universities(01:07:00) How Did Collaborations between Universities Change With the Pandemic?(01:08:29) Outlook for 2022 – Focused Research Areas(01:10:20) Big Trends in Research in 2021(01:11:00) Artificial Intelligence, Democracy, and Education(01:11:48) Astrid Woollard – Potential of Artificial Intelligence(01:13:00) Matthias Tarasiewicz – AI and Machine Learning in this decade(01:15:32) Kimberly Cornfield – Horizon Europe 2022Support the show (https://lsg2g.substack.com/subscribe?)

Join Sal's Investment Syndicate: Click to Join Listener Robert Nagle is a mathy software guy and an angel investor. We had a great chat which included his perceptions of the risks in biotech investing and also discussed some of the companies in his portfolio. This is an instructive conversation with a thoughtful angel investor. Sponsored by: Purdue University entrepreneurship Peter Fasse, patent attorney at Fish & Richardson Highlights: Sal Daher Introduces Listener Robert Nagle, Mathy Software Guy and Angel Investor Robert Nagle Was Born in Ireland & Came to the US Robert Nagle Knew Jon Hirschtick as a Brilliant Intern at Computervision [ Jon Hirschtick podcast: https://www.angelinvestboston.com/jon-hirschtick-innovating-in-the-cloud] “If you're nice to people, sometimes they remember, sometimes they don't. If you're a jerk, they always remember...” Robert Nagle's First Angel Check – Startup Making Bespoke Eyeglass Frames Conversation About Virtual Angel Investing “...many fascinating opportunities that spill out of the universities...” “That model that serves virtually-based, tool-based, asynchronous doesn't depend on a meeting is one of the exciting innovations that I think TBD Angels has brought to fruition.” “I think more than one model is good for angels. The aggregate sums as you point out can be comparable.” Robert Nagle Belongs to Hub Angels, Sky Ventures and TBD Angels Two Brothers in Law: How They Help Sal's Angel Investing Robert Nagel on His Portfolio Company Easyship Robert Nagel on His Portfolio Company NODE40 – Pickaxe & Shovels for Crypto Sal Daher on Portfolio Company Meenta – A COVID Rocketship Rockstep Solutions – ERP for Pre-Clinical Trials VistaPath Bio – Machine Vision Helping the Intake of Pathology Samples “...what holds you back from investing in life science companies?” Sal's Mentor on Life Science Company Was a Life Science Skeptic Having Made His Money in the Space “...life science companies...are taking over the value of the portfolio. That's where all the value creation is going on.” Said of SQZ: “...I'm putting my money on the fact that they have a technology that helps other people produce their therapies faster, more efficiently.” Said of Savran Technologies: “A few million dollars is enough to develop two use cases in a company like that.” The Subset of Biotech Companies that Interests Sal Daher, CFA How Sal Daher, CFA Made a Good Chunk of His Net Worth on a Scary Asset “At one point I had my kid's tuition money in Nigerian promissory notes. You'll probably say, "Majnun," that's Arabic for crazy.” “That taught me a lesson that a particular area, a particular asset that people don't like at all, they turn their noses at it. There, I will find opportunity.” Why Life Science Companies Are Paradoxically Accessible to Intelligent Lay People “I don't think the challenge is people being unable to see the opportunity. I think the problem is...on the risk side.” The Weird & Wonderful Story of Bacteria That Glow in the Dark Robert Nagle on Marc Andreessen's Thesis about Founder-Led Companies “I'm always gratified when I talk to a listener. I have yet to be disappointed, and I'm also surprised at the number of people come up to me and say, "I started my startup because of listening to your podcast."” Topics: angel investing strategies, biotech

In this episode, we sat down with Jamil Beg, Partner at 5AM Ventures, a leading venture capital firm focused on building next-generation life science companies. We discuss Jamil's career journey, the challenges in scaling early-stage biotech companies, the current life science investing landscape, and much more.Founded in 2002, 5AM has invested in 100 companies and raised over $2.0 billion since inception. Through its 4:59 Initiative, 5AM discovers, incubates, and funds breakthrough science by partnering with academics and entrepreneurs to establish proof-of-concept data that will enable a Series A financing. 5AM has offices in Boston and San Francisco.

Guy has a conversation with Dan Landry about Antimicrobial Stewardship, Evaluating certain aspects of Biotech Companies, Human Diagnostics, the future of the MiQlab and more…. Follow Dan on Twitter @Dan_Landry and check out his new website Rxplanation.com !

The Federal Trade Commission is taking action to block a biotech merger that will ultimately hinder the fight against cancer. Is it time to abolish this destructive agency? Steve Forbes on how this government body is doing more harm than good and on why the White House and Congress should act now.Steve Forbes shares his What's Ahead Spotlights each Tuesday, Thursday and Friday.

Llewellyn King discusses the hurdles for innovative drug development at small biotech companies with Linda Marbán, CEO of Capricor Therapeutics and Angelos Stergiou, MD, President and CEO, STELLAS Life Sciences Group, Inc.

Biotech companies trying to deceive Americans into COVID acceptance with tactics to create vaccine demand

Greg's LinkedIn: https://www.linkedin.com/in/johnsongreg/ Text Me: (949) 415-6256 My podcast is Random Musings From The Clinical Trials Guru Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7a GET THE BOOK! https://www.amazon.com/dp/1090349521/... Text "guru" to 855-942-5288 to join VIP list! My blog: http://www.TheClinicalTrialsGuru.com My Private Member Patreon Page: http://www.patreon.com/dansfera My CRO and Site Network: http://www.DSCScro.com My CRA Academy: http://www.TheCRAacademy.com My CRC Academy: http://www.TheCRCacademy.com Latinos In Clinical Research: http://www.LatinosinClinicalResearch.com My TikTok: DanSfera

On today's episode, meet Dean Wetherbee. Dean is the Managing Director of Creative for Ten Bridge Communications in Boston, MA, which bills itself as Biotech's Communications Partner, an agency guiding biotechs through all stages of growth. Dean has deep experience in strategic and creative marketing. He's worked in a global agency working with large pharma, emerging biotech, nonprofits and medical device and diagnostics companies. He's been involved in life sciences for over 20 years and he is passionate about getting treatments to patients.

Selling options against Biotech companies frequently generate impressive premium returns. This podcast will discuss the relationship between implied volatility and option premium. Option calculations, exit, strategies, and chart analysis will be addressed in this presentation BECOME A BCI MEMBER TODAY: https://www.thebluecollarinvestor.com/membership/ SEE BCI COURSE & PRODUCTS : https://thebluecollarinvestor.com/store/ STOCKS,TRADING,STOCK MARKET,COVERED CALLS,covered call writing,Axsome,Therapeutics,Ellman Calculator,gap-up,cost-to-close,implied volatility,Alpha,Beta,seeking,alpha,cost-basis,time-value,intrinsic- value,put-selling,collar calculator,put calculator,stock option,facebook stock,amazon stock,investing,options,Option,option buyer,strike price,in the money,in the money coverd call,out of the money covered call,covered call writing exit strategies

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Dr Srikanth Rajagopal (or Doc, as he is fondly referred to). Doc, a partner at DRG Consulting, whose areas of expertise include product and portfolio strategy to name a few, chatted to us about common strategic challenges biotechnology companies face during the process of translating a discovery into a tangible medicine. Doc gives invaluable insight for bio-pharma companies who are making development and/or commercializing decisions for their clinical programs both for those developing in house and those considering out licensing. He explores pertinent examples of how companies can go about understanding the commercial opportunity of their efficacious treatments in various scenarios and markets (including orphan indications) and discusses what he calls the 'magic triangle' to get an asset to market as fast as possible. See acast.com/privacy for privacy and opt-out information.

The Biotech sector is a key player in driving biopharma innovation and developing ground-breaking treatments for patients. Supporting the growth of this sector is vital to ensure that R&D efforts continue, both now and in the future. However, like most industries, this sector faces a complex set of challenges. Over the past six months, the biotech sector has rapidly pivoted to respond to the challenge of the COVID-19 pandemic. Companies have grappled with this new reality by adapting to a new way of working and by forging new partnerships across the sector. In the next six months, companies will need to navigate the challenges associated with Brexit including planning for possible workforce related issues and a possible new regulatory environment. In the fourth episode of Life Sciences Connect, we explore the challenges and opportunities facing the Biotech Industry.  

Biotech companies are critical. They work on projects and products that are live saving. How many of us engage with biotech companies closely? David Langsam has done so for many years. He is the editor of Biotech Daily, which is a publication that chronicles developments in the sector. He talks about companies and how they do what they do, the way in which businesses have coped through COVID and reflects on aspects of journalism and commentary over the past few months. See acast.com/privacy for privacy and opt-out information.

Former executive Art Chou lends his expertise to the locally-based company's sale. He's currently with Stadia Ventures. Matt Menietti of GlobalHack explains how coders can help immigrants. Donn Rubin of BioSTL and GlobalSTL and Ginger Imster from STL Partnership talks about why foreign tech companies are choosing St. Louis for their North American presence.

To improve the long-term value of biopharmaceutical companies, management should learn to think more like activist investors, according to a new report from EY. The report argues that capital allocation and strategic decision-making could benefit from company leaders setting aside their assumptions and challenging themselves by thinking more like outsiders. We spoke to Jeff Greene, Global Life Sciences Transaction Advisory Services Leader for EY, about the report, what industry executives could learn from activists, and whether shareholder activists indeed have a track record worth emulating.